The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Autoantibodies to tumor‐associated antigens: reporters from the immune system
Open accessAbstract
Summary: Although autoantibodies have been recognized as participants in pathogenesis of tissue injury, the collateral role of autoantibodies as reporters from the immune system identifying cellular participants in tumorigenesis has not been fully appreciated. The immune system appears to be capable of sensing aberrant structure, distribution, and function of certain cellular components involved in tumorigenesis and making autoantibody responses to the tumor‐associated antigens (TAAs). Autoantibodies to TAAs can report malignant transformation before standard clinical studies and may be useful as early detection biomarkers. The autoantibody response also provides insights into factors related to how cellular components may be rendered immunogenic. As diagnostic biomarkers, specific TAA miniarrays for identifying autoantibody profiles could have sufficient sensitivity in differentiating between types of tumors. Such anti‐TAA profiles could also be used to monitor response to therapy. The immune system of cancer patients reveals the immune interactive sites or the autoepitopes of participants in tumorigenesis, and this information should be used in the design of immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Conserved Structures and Diversity of Functions of RNA-Binding Proteins
Burd, C. G., & Dreyfuss, G. (1994) · Science · doi:10.1126/science.8036511 · Cited by 1,877
Antinuclear Antibodies: Diagnostic Markers for Autoimmune Diseases and Probes for Cell Biology
Tan, E. M. (1989) · Advances in Immunology · doi:10.1016/s0065-2776(08)60641-0 · Cited by 1,514
Self-citationFunctional identity of proliferating cell nuclear antigen and a DNA polymerase-δ auxiliary protein
Prelich, G., Tan, C.-K., Kostura, M., Mathews, M. B., So, A. G., Downey, K. M., & Stillman, B. (1987) · Nature · doi:10.1038/326517a0 · Cited by 1,059
(2006) · Elsevier eBooks · doi:10.1016/b978-0-12-595961-2.x5000-8 · Cited by 962
Autoantibody to a nuclear antigen in proliferating cells
Miyachi, K., Fritzler, M. J., & Tan, E. M. (1978) · The Journal of Immunology · doi:10.4049/jimmunol.121.6.2228 · Cited by 874
Self-citationNielsen, J., Christiansen, J., Lykke-Andersen, J., Johnsen, A. H., Wewer, U. M., & Nielsen, F. C. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1262 · Cited by 721
Autoantigen microarrays for multiplex characterization of autoantibody responses
Robinson, W. H., DiGennaro, C., Hueber, W., Haab, B. B., Kamachi, M., Dean, E. J., Fournel, S., Fong, D., Genovese, M. C., De Vegvar, H. E. N., et al. (2002) · Nature Medicine · doi:10.1038/nm0302-295 · Cited by 673
p53 Antibodies in the sera of patients with various types of cancer: a review.
Soussi, T. (2000) · PubMed · Cited by 643
Epitopes on protein antigens: Misconceptions and realities
Laver, W. G., Air, G. M., Webster, R. G., & Smith-Gill, S. J. (1990) · Cell · doi:10.1016/0092-8674(90)90464-p · Cited by 533
An auxiliary protein for DNA polymerase-delta from fetal calf thymus.
Tan, C. K., Castillo, C., So, A. G., & Downey, K. M. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67240-0 · Cited by 495
Woessner, R. D., Mattern, M. R., Mirabelli, C. K., Johnson, R. K., & Drake, F. H. (1991) · PubMed · Cited by 455
Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer
Crawford, L. V., Pim, D. C., & Bulbrook, R. D. (1982) · International Journal of Cancer · doi:10.1002/ijc.2910300404 · Cited by 450
Regulation of Proliferating Cell Nuclear Antigen during the Cell Cycle
Morris, G. F., & Mathews, M. B. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)80079-5 · Cited by 447
Profiles of Antinuclear Antibodies in Systemic Rheumatic Diseases
Notman, D. D., KURATA, N., & TAN, E. M. (1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-83-4-464 · Cited by 365
Self-citationRinke, J., & STEITZ, J. A. (1982) · Cell · doi:10.1016/0092-8674(82)90099-x · Cited by 357
A nuclear antigen associated with cell proliferation and blast transformation.
Takasaki, Y., Deng, J. S., & Tan, E. M. (1981) · The Journal of experimental medicine · doi:10.1084/jem.154.6.1899 · Cited by 329
Self-citationAutoimmune type 1 diabetes: resolved and unresolved issues
Notkins, A. L., & Lernmark, Å. (2001) · Journal of Clinical Investigation · doi:10.1172/jci14257 · Cited by 323
Serum p53 antibodies as early markers of lung cancer
Lubin, R., Zalcman, G., Bouchet, L., Trédaniel, J., Legros, Y., Cazals, D., Hirsch, A., & Soussi, T. (1995) · Nature Medicine · doi:10.1038/nm0795-701 · Cited by 318
The Sentinel Within: Exploiting the Immune System for Cancer Biomarkers
Anderson, K. S., & LaBaer, J. (2005) · Journal of Proteome Research · doi:10.1021/pr0500814 · Cited by 314
Why is Hu where? Shuttling of early-response-gene messenger RNA subsets
Keene, J. D. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.5 · Cited by 294
Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein
Müeller-Pillasch, F., Lacher, U., Wallrapp, C., Micha, A., Zimmerhackl, F., Hameister, H., Varga, G., Friess, H., Büchler, M., Beger, H. G., et al. (1997) · Oncogene · doi:10.1038/sj.onc.1201110 · Cited by 284
A microarray enzyme-linked immunosorbent assay for autoimmune diagnostics
Joos, T. O., Schrenk, M., Höpfl, P., Kröger, K., Chowdhury, U., Stoll, D., Schörner, D., Dürr, M., Herick, K., Rupp, S., et al. (2000) · Electrophoresis · doi:10.1002/1522-2683(20000701)21:13<2641::aid-elps2641>3.0.co;2-5 · Cited by 280
Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens.
Zhang, J.-Y., Casiano, C. A., Peng, X.-X., Koziol, J. A., Chan, E. K. L., & Tan, E. M. (2003) · PubMed · Cited by 270
Self-citationSelective cleavage of nuclear autoantigens during CD95 (Fas/APO-1)-mediated T cell apoptosis.
Casiano, C. A., Martin, S. J., Green, D. R., & Tan, E. M. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.2.765 · Cited by 264
Self-citationProliferation-dependent regulation of DNA topoisomerase II in cultured human cells.
Hsiang, Y. H., Wu, H. Y., & Liu, L. F. (1988) · PubMed · Cited by 247
Autoantibody to RNA polymerase I in scleroderma sera.
Reimer, G., Rose, K. M., Scheer, U., & Tan, E. M. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112809 · Cited by 237
Self-citationIdentification of tumor antigens in renal cell carcinoma by serological proteome analysis
Klade, C. S., Voss, T., Krystek, E., Ahorn, H., Zatloukal, K., Pummer, K., & Adolf, G. R. (2001) · PROTEOMICS · doi:10.1002/1615-9861(200107)1:7<890::aid-prot890>3.0.co;2-z · Cited by 213
Serological analysis of human tumor antigens: molecular definition and implications
Şahin, U., & Pfreundschuh, M. G. (1997) · Molecular Medicine Today · doi:10.1016/s1357-4310(97)01081-2 · Cited by 210
Zhang, J.-Y., Chan, E. K. L., Peng, X.-X., & Tan, E. M. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.7.1101 · Cited by 202
Self-citationDiagnostic Markers of Ovarian Cancer by High-Throughput Antigen Cloning and Detection on Arrays
Chatterjee, M., Mohapatra, S., Ionan, A., Bawa, G., Ali-Fehmi, R., Wang, X., Nowak, J., Ye, B., Nahhas, F. A., Lu, K., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-04-2962 · Cited by 202
Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis
Tan, E. M. (2001) · Journal of Clinical Investigation · doi:10.1172/jci14451 · Cited by 199
Self-citationCariani, E., Lasserre, C., Seurin, D., Hamelin, B., Kemeny, F., Franco, D., Czech, M., Ullrich, A., & Bréchot, C. (1988) · PubMed · Cited by 193
Doyle, G. A. R., Leeds, P. F., Fleisig, A. J., Ross, J., Betz, N. A., & Prokipcak, R. D. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.22.5036 · Cited by 177
Recursive partitioning as an approach to selection of immune markers for tumor diagnosis.
Koziol, J. A., Zhang, J.-Y., Casiano, C. A., Peng, X.-X., Shi, F., Feng, A. C., Chan, E. K. L., & Tan, E. M. (2003) · PubMed · Cited by 175
Self-citationRapoport, B., & McLachlan, S. M. (2001) · Journal of Clinical Investigation · doi:10.1172/jci14321 · Cited by 175
Lubin, R., Schlichtholz, B., Bengoufa, D., Zalcman, G., Trédaniel, J., Hirsch, A., de Fromentel, C. C., Preudhomme, C., Fenaux, P., Fournier, G., et al. (1993) · PubMed · Cited by 173
Richter, W., Shi, Y., & Baekkeskov, S. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.7.2832 · Cited by 172
Bernat, R. L., Borisy, G. G., Rothfield, N. F., & Earnshaw, W. C. (1990) · The Journal of Cell Biology · doi:10.1083/jcb.111.4.1519 · Cited by 145
Mahoney, J. A., & Rosen, A. (2005) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.09.018 · Cited by 143
Schmid, C. (1995) · Cell Biology International · doi:10.1006/cbir.1995.1088 · Cited by 142
Hepatitis B virus, the vaccine, and the control of primary cancer of the liver
Blumberg, B. S. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7121 · Cited by 140
Kao, H., Marto, J. A., Hoffmann, T. K., Shabanowitz, J., Finkelstein, S. D., Whiteside, T. L., Hunt, D. F., & Finn, O. J. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.9.1313 · Cited by 140
Analysis of the anti-p53 antibody response in cancer patients.
Labrecque, S., Naor, N., Thomson, D. M., & Matlashewski, G. (1993) · PubMed · Cited by 136
Soares, M., Mehta, V., & Finn, O. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6555 · Cited by 135
Trivers, G. E., Benedetti, V. M. D., Cawley, H., Caron, G., Harrington, A. M., Bennett, W. P., Jett, J. R., Colby, T. V., Tazelaar, H. D., Pairolero, P. C., et al. (1996) · PubMed · Cited by 128
Imai, H., Chan, E. K. L., Kiyosawa, K., Fu, X., & Tan, E. M. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116848 · Cited by 122
Self-citationMusunuru, K., & Darnell, R. B. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.239 · Cited by 122
MULTIPLEXED PROTEIN ARRAY PLATFORMS FOR ANALYSIS OF AUTOIMMUNE DISEASES
Balboni, I., Chan, S. M., Kattah, M. G., Tenenbaum, J. D., Butte, A. J., & Utz, P. J. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090709 · Cited by 119
Aberrant Expression of Fetal RNA-Binding Protein p62 in Liver Cancer and Liver Cirrhosis
Lu, M., Nakamura, R. M., Dent, E. D., Zhang, J.-Y., Nielsen, F. C., Christiansen, J., Chan, E. K. L., & Tan, E. M. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)61770-1 · Cited by 118
Self-citationSuzuki, H., Graziano, D. F., McKolanis, J., & Finn, O. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0538 · Cited by 113
Cancer vaccines: progress reveals new complexities
Yu, Z., & Restifo, N. P. (2002) · Journal of Clinical Investigation · doi:10.1172/jci16216 · Cited by 107
Inefficient Clearance of Dying Cells and Autoreactivity
Gaipl, U. S., Sheriff, A., Franz, S., Munoz, L. E., Voll, R. E., Kalden, J. R., & i, M. H. (2006) · Springer eBooks · doi:10.1007/3-540-29714-6_8 · Cited by 103
Martinez, N. R., Augstein, P., Moustakas, A. K., Papadopoulos, G. K., Gregori, S., Adorini, L., Jackson, D. C., & Harrison, L. C. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17166 · Cited by 97
Parry, N. R., Barnett, P. V., Ouldridge, E. J., Rowlands, D. J., & Brown, F. (1989) · Journal of General Virology · doi:10.1099/0022-1317-70-6-1493 · Cited by 92
Cyclin B1 and Other Cyclins as Tumor Antigens in Immunosurveillance and Immunotherapy of Cancer
Egloff, A. M., Vella, L. A., & Finn, O. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3389 · Cited by 91
Tan, C., Sullivan, K. F., Li, X., Tan, E. M., Downey, K. M., & So, A. G. (1987) · Nucleic Acids Research · doi:10.1093/nar/15.22.9299 · Cited by 88
Self-citationImmune Response to Cyclin B1 in Hepatocellular Carcinoma
Covini, G., Chan, E. K. L., Nishioka, M., MORSHED, S. A., Reed, S. I., & Tan, E. M. (1997) · Hepatology · doi:10.1002/hep.510250114 · Cited by 85
Self-citationAmplification in human breast cancer of a gene encoding a c-myc mRNA-binding protein.
Doyle, G. A. R., Bourdeau-Heller, J. M., Coulthard, S., Meisner, L. F., & Ross, J. (2000) · Cancer Research · Cited by 82
C‐MYC and IGF‐II mRNA‐binding protein (CRD‐BP/IMP‐1) in benign and malignant mesenchymal tumors
Ioannidis, P., Trangas, T. T., Dimitriadis, E., Samiotaki, M. K., Kyriazoglou, I., Tsiapalis, C. M., Kittas, C. N., Agnantis, N., Nielsen, F. C., Nielsen, J., et al. (2001) · International Journal of Cancer · doi:10.1002/ijc.1512 · Cited by 82
Imai, H., Nakano, Y., Kiyosawa, K., & Tan, E. M. (1993) · Cancer · doi:10.1002/1097-0142(19930101)71:1<26::aid-cncr2820710106>3.0.co;2-n · Cited by 76
Self-citationYu, M., Zhan, Q., & Finn, O. J. (2002) · Molecular Immunology · doi:10.1016/s0161-5890(02)00026-3 · Cited by 74
Fosså, A., Alsøe, L., Crameri, R., Funderud, S., Gaudernack, G., & Smeland, E. B. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0458-8 · Cited by 73
Autoimmune Responses to mRNA Binding Proteins p62 and Koc in Diverse Malignancies
Zhang, J.-Y., Chan, E. K. L., Peng, X.-X., Lu, M., Wang, X., Mueller, F., & Tan, E. M. (2001) · Clinical Immunology · doi:10.1006/clim.2001.5048 · Cited by 71
Self-citationAn efficient proteomics-based approach for the screening of autoantibodies
Canelle, L., Bousquet, J., Pionneau, C., Deneux, L., Imam-Sghiouar, N., Caron, M., & Joubert‐Caron, R. (2005) · Journal of Immunological Methods · doi:10.1016/j.jim.2005.01.015 · Cited by 64
Profiling the immune response in patients with breast cancer by phage-displayed cDNA libraries
Sioud, M., & Hansen, M. H. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200103)31:3<716::aid-immu716>3.0.co;2-9 · Cited by 61
Shi, F., Zhang, J., Liu, D., Rearden, A., Elliot, M. L., Nachtsheim, D., Daniels‐Wells, T. R., Casiano, C. A., Heeb, M. J., Chan, E. K. L., et al. (2004) · The Prostate · doi:10.1002/pros.20181 · Cited by 59
Self-citationBergsland, E. K., & Venook, A. P. (2000) · Current Opinion in Oncology · doi:10.1097/00001622-200007000-00013 · Cited by 51
Insulin-like growth factors: the unrecognised oncogenes
Westley, B., & May, F. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.465 · Cited by 48
Posner, J. B., & Dalmau, J. O. (1997) · Current Opinion in Immunology · doi:10.1016/s0952-7915(97)80055-6 · Cited by 43
Relative paradigms between autoantibodies in lupus and autoantibodies in cancer
Tan, E. M., & SHI, F.-D. (2003) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2003.02259.x · Cited by 35
Self-citationPowers, A. C., Bavik, K., Tremble, J. M., Daw, K., Scherbaum, W. A., & Banga, J. P. (1999) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1999.01030.x · Cited by 34
Plant DMA topoisomerase I is recognized and inhibited by human Scl-70 sera autoantibodies
Agris, P. F., Parks, R., Bowman, L., Guenther, R. H., Kovacs, S. A., & Pelsue, S. C. (1990) · Experimental Cell Research · doi:10.1016/0014-4827(90)90247-8 · Cited by 20
Peptide-based treatment for autoimmune diseases: learning how to handle a double-edged sword
Pugliese, A. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18395 · Cited by 15
Lindbladh, I., Svärd, A. A., & Lernmark, Å. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812102-3.00041-5 · Cited by 8
Cited by
Fuertes, M. B., Kacha, A. K., Kline, J., Woo, S.-R., Kranz, D. M., Murphy, K. M., & Gajewski, T. F. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101159 · Cited by 1,192
Serum autoantibodies as biomarkers for early cancer detection
Tan, H. T., Low, J., Lim, S. G., & Chung, M. C. M. (2009) · The FEBS Journal · doi:10.1111/j.1742-4658.2009.07396.x · Cited by 315
Zaenker, P., Gray, E. S., & Ziman, M. R. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.01.017 · Cited by 267
Overexpression of HCC1/CAPERα may play a role in lung cancer carcinogenesis
Chai, Y., Liu, X., Dai, L., Li, Y., Liu, M., & Zhang, J.-Y. (2014) · Tumor Biology · doi:10.1007/s13277-014-1819-y · Cited by 42
Self-citationLiu, W., Li, Z., Xu, W., Wang, Q., & Yang, S. (2013) · Scandinavian Journal of Immunology · doi:10.1111/sji.12032 · Cited by 33
Metadata
- Authors
- Tan, E. M., & Zhang, J.
- Venue
- Immunological Reviews
- Publisher
- Wiley
- Published
- 2008-03-19
- Volume
- 222
- Issue
- 1
- Pages
- 328-340
- ISSN
- 0105-2896 (ISSN-L)
- 1600-065X
- OpenAlex
- W2014523497
- Cited by
- 309
- References
- 74
- FWCI
- 0.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.